Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S2W-21268 · Session 2

Further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005, why the Scottish Medicines Consortium does not recommend t…

Answered Asked by Alex Neil SNP Lodged 30 Nov 2005

The question

To ask the Scottish Executive, further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005, why the Scottish Medicines Consortium does not recommend that Memantine (Exiba ®) is used to treat moderately severe to severe Alzheimer’s Disease and whether this indicates that the drug is used to treat milder cases of Alzheimer’s Disease.

The answer

Answered by Andy Kerr on 12 Dec 2005 · 12 days after it was lodged, on time

The Scottish Medicines Consortium (SMC) reviewed memantine (Ebixa) in July 2003 and did not recommend it for use within NHS Scotland. Its advice was that, although this is currently the only agent licensed for use in moderately severe to severe Alzheimer's disease, the magnitude of the effect is extremely small. Compared with placebo it is associated with a statistically significant reduction in the rate of deterioration in global, functional and cognitive scales. On the evidence presented, the associated gains appear to be marginal relative to the overall costs.
The company subsequently made a resubmission to SMC for assessment and in December 2003 SMC did not recommend it for use. The economic case submitted by the manufacturer did not suggest that use of this drug would be cost effective relative to standard practice in Scotland.
The licensed indication submitted for review was for the treatment of patients with moderately severe to severe Alzheimer's disease and SMC therefore commented on this indication only.

In the Official Report

No contribution in the Official Report cites S2W-21268 by reference.